Clinical trial of montelukast combined with loratadine in the treatment of patients with allergic rhinitis
10.13699/j.cnki.1001-6821.2024.24.003
- VernacularTitle:孟鲁司特联合氯雷他定治疗变应性鼻炎患者的临床研究
- Author:
Yin FU
1
;
Sheng LI
1
;
Jin-shan LAN
1
;
Hui-mei LI
1
;
Jing XU
1
;
Shao-jun XU
1
Author Information
1. 衢州市人民医院 耳鼻咽喉科,浙江 衢州 324000
- Publication Type:Journal Article
- Keywords:
montelukast tablet;
loratadine tablet;
allergic rhinitis;
inflammatory factor;
recurrence rate
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(24):3533-3537
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of montelukast tablets combined with loratadine tablets in the treatment of allergic rhinitis(AR).Methods AR patients were divided into control group and treatment group according to the cohort method.The control group was given 10 mg of loratadine tablets orally once a day.On this basis,the treatment group was given 10 mg of montelukast tablets orally once a day.Both groups were treated for 8 weeks.Clinical efficacy,nasal symptom scores,inflammation cells and mediators[eosinophil cationic protein(ECP)and eosinophil(EOS)],immunoglobulin E(IgE),inflammatory factors[interleukin-6(IL-6),interleukin-8(IL-8)and interleukin-10(IL-10)],nasal mucosal tissue growth factor[insulin growth factor-1 receptor(IGF-IR),fibrogrowth factor-2(FGF-2)],and recurrence rate were compared between the two groups.And evaluated safety.Results After treatment,the total effective rates in the treatment group and the control group were 95.10％(97 cases/102 cases)and 80.61％(79 cases/98 cases),with statistically significant difference(P＜0.05).After treatment,visual analogue scale(VAS)scores for nasal symptoms in the treatment group and the control group were 1.25±0.16 and 3.01±0.70;ECP levels were(370.18±13.34)and(457.31±17.60)ng·mL-1;EOS were(2.95±0.53)％and(3.98±1.14)％;IgE levels were(119.37±7.65)and(179.55±11.63)U·mL-1;IL-6 levels were(106.27±7.13)and(135.41±10.90)ng·L-1;IL-8 levels were(108.36±6.72)and(129.47±10.33)ng·L-1;IL-10 levels were(17.14±4.55)and(13.59±3.76)ng·L-1;IGF-IR were 3.70±0.63 and 2.47±0.51;FGF-2 were 3.93±0.72 and 2.19±0.40.There were statistically significant differences in the above indexes between the treatment group and the control group(all P＜0.05).The recurrence rates in the treatment group and the control group at 6 and 12 months after treatment were 7.84％and 17.35％,15.69％and 25.51％.The differences were statistically significant(all P＜0.05).Adverse drug reactions in the treatment group mainly included nausea,weakness,headache and diarrhea.Adverse drug reactions in the control group mainly included nausea,weakness and headache.The total incidence rates of adverse drug reactions in the treatment group and the control group were 5.88％and 4.08％,without statistically significant difference(P＞0.05).Conclusion Compared with loratadine tablets,montelukast tablets combined with loratadine tablets is more effective in the treatment of AR,without increasing adverse drug reactions.
